<DOC>
	<DOCNO>NCT02462369</DOCNO>
	<brief_summary>This study compare effect microalbuminuria improvement type 2 diabetes mellitus ( T2DM ) treat saxagliptin glimepiride.All patient receive metformin and/or acarbose , randomly receive saxagliptin ( 5mg/d ) glimepiride ( 1-4mg/d ) .</brief_summary>
	<brief_title>Saxagliptin 's Effects Microalbuminuria Improvement Type 2 Diabetic Patients</brief_title>
	<detailed_description>Both sitagliptin glimepiride hypoglycemic agent , different mechanisms.sitagliptin delay degradation glucagon-like peptide -1 ( GLP-1 ) inhibit DPPIV decrease serum glucose level.glimepiride stimulate islet B cell secrete insulin decrease serum glucose level . Preclinical study several clinical trial ( include vildagliptin , sitagliptin , linagliptin , exenatide ) suggest DPP-4i/GLP-1 might potential low albuminuria , albumin-creatinine ratio ( ACR ) improve glomerular filtration rate ( GFR ) effect might independent change glucose control . Recently , SAVOR outcomes also show saxagliptin might nephroprotective effect , proportion patient microalbuminuria convert normal albuminuria saxagliptin treatment 1 year 31.3 % , mechanism still unclear .</detailed_description>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Diagnosed type 2 diabetes stable , dose metformin ( 1000mg~2550mg/d ) acarbose ( 100mg~300mg/d ) least 60 day 3 . Men woman ( nonpregnant use medically approve birthcontrol method ) age age ≥20 ≤70 year screen 4 . HbA1c ≥ 7.0 % ≤ 9.0 % screen 5 . 24hour urinary albumin level 30300 mg/24 h 1．Women , pregnant , intend become pregnant study period , currently lactate female , woman childbearing potential use highly effective , medically approve birth control method . 2 . Diagnosis history : Type 1 diabetes mellitus , diabetes result pancreatic injury secondary form diabetes , e.g acromegaly Cushing 's syndrome . Acute metabolic diabetic complication ketoacidosis hyperosmolar coma within past 6 month . 3 . Previous treatment dipeptidyl peptidase4 ( DPP4 ) inhibitor GLP1 receptor agonist within past 6 months． 4 . History hypersensitivity reaction ( e.g. , anaphylaxis , angioedema , exfoliative skin condition ) dipeptidyl peptidase4 inhibitor ( DPP4 ) , glimepiride , metformin acarbose . 5 . Treatment systemic glucocorticoid ( oral , intravenous ) consecutive 7 day within past 6 month . 6 . Triglycerides ( fast ) &gt; 4.5 mmol/L ( &gt; 400 mg/dL ) screening within 4 week prior screen . 7 . Patients clinically apparent liver disease characterize either one following : alanine aminotransferase ( ( ALT ) aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) confirm two consecutive measurement within 4 week prior screen period Impaired excretory ( eg , hyperbilirubinemia ) and/or synthetic function , condition decompensated liver disease coagulopathy , hepatic encephalopathy , hypoalbuminemia , ascites bleed oesophageal varix . Acute viral active autoimmune , alcoholic , type hepatitis . 8 . Patients moderate /severe renal impairment endstage renal disease ( CrCl ≤ 50 mL/min ) screening within 4 week prior screen 9 . Congestive heart failure define New York Heart Association ( NYHA ) class III IV . 10 . Significant cardiovascular history within past 3 month prior screen define : myocardial infarction , coronary angioplasty bypass graft ( ) , valvular disease repair , unstable angina pectoris , transient ischemic attack , cerebrovascular accident . 11 . History chronic pancreatitis idiopathic acute pancreatitis . 12 . History gastrointestinal disease include gastroenterostomy , enterectomy , severe hernia , intestinal obstruction , intestinal ulcer . 13 . History medullary thyroid carcinoma . 14 . History alcohol abuse illegal drug abuse within past 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>